Lazard Asset Management
CRNX icon

Lazard Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Lazard Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,612
Closed -$408K – 2412
2022
Q1 		$408K Buy
+18,612
New +$377K ﹤0.01% 1135

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Lazard Asset Management's CRNX Position: Q2 2022 in Review

Lazard Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2022, closing a stake of 18,612 shares — an estimated $408K sold.

Lazard Asset Management first reported a position in CRNX in Q1 2022 and held it in 1 quarter. The position peaked at $408K in Q1 2022. 111 funds tracked by Wall St. Rank hold CRNX as of Q2 2022.

  • Lazard Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Lazard Asset Management sold 18,612 Crinetics Pharmaceuticals shares in Q2 2022, an estimated $408K.
  • Lazard Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Lazard Asset Management's Crinetics Pharmaceuticals position peaked at $408K in Q1 2022.
  • 111 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2022.

Based on Lazard Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.